In recent times, targeted DNA/RNA sequencing has gained the global recognition as a key technology in research activities in the field of life science. It allows assessment of specific region of interest while maintaining complexity of data and sequence cost under manageable limits. Whole Genome and Exome Sequencing (WGS/WES) provides information on the whole sequence, however, it consumes time and requires high capital. Owing to its high flexibility and economic benefits, targeted sequencing is gaining preference in WGS/WES.
Sanger Sequencing to Lose Shares to NGS Technology
On the basis of technology, targeted DNA/RNA sequencing can be classified into Next-Generation Sequencing (NGS) and others, including Sanger sequencing. Demand for NGS-based methods will remain higher than their counterparts through 2025. The presence of a large number of high-throughput sequencers for examining mutations in a specific region of a genome is contributing to their demand. They allow screening hundreds to thousands of genes at a relatively lower cost, which is likely to supplement the segment growth. High success rate of the NGS technology is further boosting its adoption in new genome projects.
To put this in perspective, recently, Fusion Genomics announced that they are developing an assay, OneTest PathoGenome that can be used for diagnosis of infectious diseases. The assay is being developed using a combination of DNA/RNA capture probes, universal sample prep, and NGS. Besides this, increasing investments in the advancements of NGS technology will support the segment development. The NGS technology is expected to make inroads in the shares of Sanger sequencing, owing to its higher scalability and sensitivity as compared to the latter. Nevertheless, wherever workflow is concerned, Sanger method edges over second-generation sequencing methods.
Market Insights
As per the findings of Grand View Research Inc., the global targeted DNA/RNA sequencing market is estimated to rise to a valuation of USD 15.9 billion by 2025. Increasing R&D activities, to demonstrate a considerable reduction in the cost per sample by sequencing, is likely to work in favor of the market. Technological advancements in targeted DNA/RNA sequencing to standardize and simplify the sequence processes and cut down presequencing time is anticipated to play a pivotal role in the development of this market.
North America will hold a prominent position in the market throughout the forecast period (from 2018 to 2025). Presence of a significant number of genome centers along with favorable regulatory scenario is propelling the regional market. Some of the key companies in the market are F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; Illumina, Inc.; Thermo Fisher Scientific, Inc.; and Agilent Technologies.
No comments:
Post a Comment